SCHEMBL2391376

SCHEMBL2391376

CC1(C)CCC(C)(C)c2cc(C(=O)c3ccc4cc(C(=O)O)ccc4c3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
RARB P10826 13/20 1.00
RARG P13631 12/20 1.00
RARA P10276 11/20 1.00
CYP26A1 O43174 4/20 1.00
CYP26B1 Q9NR63 3/20 1.00
RXRA P19793 7/20 0.80
RXRB P28702 6/20 0.80
RXRG P48443 4/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8439958 0.92 RARB (0.86) RARBRARGRARACYP26A1CYP26B1
SCHEMBL8523097 0.91 RARB (0.83) RARBRARGRARACYP26A1CYP26B1
SCHEMBL10355871 0.89 RXRA (1.00) RARBRARGRARACYP26A1CYP26B1
SCHEMBL29827631 0.89 RARB (0.81) RARBRARGRARACYP26A1CYP26B1
SCHEMBL846110 0.89 RARB (0.81) RARBRARGRARACYP26A1CYP26B1
SCHEMBL9747842 0.88 RARB (1.00) RARBRARGRARACYP26A1CYP26B1
SCHEMBL7761329 0.88 RARB (0.80) RARBRARGRARACYP26A1CYP26B1
Hydrochloric Acid SCHEMBL9120757 0.87 RARB (0.78) RARBRARGRARACYP26A1CYP26B1
SCHEMBL8733241 0.87 RARB (0.83) RARBRARGRARACYP26A1CYP26B1
SCHEMBL2331952 0.87 RARB (1.00) RARBRARGRARACYP26A1CYP26B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1227791-B1 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARS-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION OREAL (FR) 2006-11-08 EP claimed
US-20050208001-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions SOCIETE L'OREAL, S.A. (FR) 2005-09-22 US claimed
US-6686386-B1 COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-03 US claimed
US-6593359-B1 Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) 2003-07-15 US claimed
US-20030013734-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions MAIGNAN JEAN (FR) 2003-01-16 US claimed
US-20020049250-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions SOCIETE L'OREAL, S.A. (FR) 2002-04-25 US claimed
US-20010018456-A1 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis FESUS LASZLO (HU) 2001-08-30 US claimed
EP-0220118-B1 BICYCLIC NAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1992-01-02 EP claimed
CN-122095314-A Photosensitive resin laminate, method for forming resist pattern, and method for manufacturing wiring board having conductor pattern 2026-05-26 CN disclosed
CN-122029490-A Photosensitive resin laminate, method for forming resist pattern, and method for forming wiring board 旭化成株式会社 2026-05-12 CN disclosed
US-12410330-B2 Energy curable, heat activated flexographic adhesives for die-less foiling INX INTERNATIONAL INK CO. (US) 2025-09-09 US disclosed
EP-3955900-B1 POLYMERIC CAPSULES PROCTER & GAMBLE (US) 2025-07-23 EP disclosed
WO-2025134720-A1 NON-POLYMER COMPOUND AND COMPOSITION FOR FILM FORMATION 日産化学株式会社 2025-06-26 WO disclosed
CN-120077329-A Photosensitive resin composition, photosensitive resin laminate, and method for forming resist pattern 旭化成株式会社 2025-05-30 CN disclosed
WO-1999048529-A1 RETINOID-GLITAZONE COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-30 WO disclosed
EP-0808159-A1 USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1997-11-26 EP disclosed
WO-1996024344-A1 USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1996-08-15 WO disclosed
US-5489611-A ADMINISTERING A RETINOID COMPOUND WARNER-LAMBERT COMPANY (US) 1996-02-06 US disclosed
US-5004732-A Treatment of acne SOCIETE ANONYME DITE: L'OREAL (FR) 1991-04-02 US disclosed
US-4826969-A SKIN AND EYE DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049250-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions PPARG, PPARA, PPARD RARB 20/4885RARG 28/4885RARA 12/4885
US-20030013734-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions PPARG, PPARA, PPARD RARB 20/4885RARG 28/4885RARA 12/4885
US-20050208001-A1 PPAR receptor activator compounds for treating cutaneous disorders/afflictions PPARG, PPARA, PPARD RARB 23/4885RARG 28/4885RARA 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.